Together, these findings support the idea that TGF-β signaling in astrocytes promotes astrogliosis, demyelination, and chronic inflammation, and that targeting TGF-β signaling might be a promising therapeutic strategy for MS. The gene discussed is TGFB1; the disease is myeloid sarcoma.